首页> Neuro-degenerative diseases> How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

导出原文传递

翻译打印收藏纠错

第一作者： Gauthier,S.

作者： Gauthier,S. ^[1] ; Leuzy,A. ; Rosa-Neto,P.

作者单位： McGill Center for Studies in Aging, Douglas Mental Health Research Institute, 6825 LaSalle Boul., ^[1]

关键词 Alzheimer's disease Outcomes Treatments

发布时间 2014-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Neuro-degenerative diseases

2014年13卷2/3期

197-199页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

Neuro-degenerative diseases

2014年13卷2/3期

197-199页

检索历史清除

How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

Neuro-degenerative diseases

相似文献

同项目论文

Neuro-degenerative diseases

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease?

Neuro-degenerative diseases

相似文献

同项目论文

Neuro-degenerative diseases

相关期刊

检索历史清除